company background image
DR6 logo

ACADIA Pharmaceuticals DB:DR6 Stock Report

Last Price

€16.10

Market Cap

€2.7b

7D

-1.2%

1Y

-39.5%

Updated

23 Dec, 2024

Data

Company Financials +

ACADIA Pharmaceuticals Inc.

DB:DR6 Stock Report

Market Cap: €2.7b

DR6 Stock Overview

A biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. More details

DR6 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for DR6 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

ACADIA Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ACADIA Pharmaceuticals
Historical stock prices
Current Share PriceUS$16.10
52 Week HighUS$28.20
52 Week LowUS$13.06
Beta0.41
1 Month Change4.99%
3 Month Change10.61%
1 Year Change-39.47%
3 Year Change-24.24%
5 Year Change-58.52%
Change since IPO195.41%

Recent News & Updates

Recent updates

Shareholder Returns

DR6DE BiotechsDE Market
7D-1.2%-2.6%-2.0%
1Y-39.5%-13.2%6.8%

Return vs Industry: DR6 underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: DR6 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is DR6's price volatile compared to industry and market?
DR6 volatility
DR6 Average Weekly Movement5.9%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.4%
10% least volatile stocks in DE Market2.4%

Stable Share Price: DR6 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: DR6's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993620Catherine Owen Adamswww.acadia.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.

ACADIA Pharmaceuticals Inc. Fundamentals Summary

How do ACADIA Pharmaceuticals's earnings and revenue compare to its market cap?
DR6 fundamental statistics
Market cap€2.70b
Earnings (TTM)€123.48m
Revenue (TTM)€892.90m

22.2x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DR6 income statement (TTM)
RevenueUS$929.24m
Cost of RevenueUS$347.19m
Gross ProfitUS$582.05m
Other ExpensesUS$453.54m
EarningsUS$128.51m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.77
Gross Margin62.64%
Net Profit Margin13.83%
Debt/Equity Ratio0%

How did DR6 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:13
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ACADIA Pharmaceuticals Inc. is covered by 37 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
Joel BeattyBaird
Ishan MajumdarBaptista Research